256376-68-8

Basic information

• Product Name: 1H-Pyrazolo[3,4-b]pyridine-3-carboxiMidaMide, 1-[(2-fluorophenyl)Methyl]-
• Synonyms: 1H-Pyrazolo[3,4-b]pyridine-3-carboxiMidaMide, 1-[(2-fluorophenyl)Methyl]-;1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxiMidaMide
• CAS NO: 256376-68-8
• Molecular Formula: C₁₄H₁₂FN₅
• Molecular Weight: 269.2769832
• Mol File: 256376-68-8.mol

Chemical Properties

• Boiling Point: 469.0±55.0 °C(Predicted)
• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• PKA: 9.08±0.30(Predicted)
• CAS DataBase Reference: 1H-Pyrazolo[3,4-b]pyridine-3-carboxiMidaMide, 1-[(2-fluorophenyl)Methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-b]pyridine-3-carboxiMidaMide, 1-[(2-fluorophenyl)Methyl]-(256376-68-8)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-b]pyridine-3-carboxiMidaMide, 1-[(2-fluorophenyl)Methyl]-(256376-68-8)

Safety Data

• Hazardous Substances Data: 256376-68-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrazolo[3,4-b]pyridine-3-carboxamide, 1-[(2-fluorophenyl)methyl]is used as a potential antitumor agent for its potential to inhibit the growth and progression of cancer cells. Its pyrazolo[3,4-b]pyridine structure and the addition of the fluorophenylmethyl group may contribute to its enhanced biological activity and selectivity in targeting cancer cells.
Additionally, it is used as a potential anti-inflammatory agent for its potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions. 1H-Pyrazolo[3,4-b]pyridine-3-carboxiMidaMide, 1-[(2-fluorophenyl)Methyl]-'s structure and modifications may allow for targeted delivery and increased efficacy in treating inflammatory diseases.

Upstream product

• 1313738-72-5 1-(2-fluorobenzyl)-3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 446-48-0 o-fluorobenzyl bromide 
• 117007-52-0 3-iodo-1H-pyrazolo[3,4-b]pyridine 
• 256376-59-7 ethyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate 
• 256376-62-2 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide 
• 256504-39-9 ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate 
• 51859-98-4 (2-fluorobenzyl)hydrazine 
• 304874-06-4 methyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbimidate 

Downstream Products

• 428854-24-4 2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidine-4,5,6- triamine 
• 457914-32-8 2-({4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}amino)ethanol 
• 370879-47-3 N'-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidine-4,5,6-triamine 
• 625115-55-1 Riociguat 
• 1702271-98-4 2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-N-methylpyrimidine-4,5,6-triamine 
• 370879-49-5 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-[(E)-phenyldiazen-1-yl]pyrimidine-4,6-diamine 
• 402595-29-3 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-pyridinyl)-4-pyrimidineamine 
• 651340-91-9 3-(5-bromo-2-pyrimidinyl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine 
• 651348-32-2 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-methyl-4-pyrimidinol 

Relevant articles and documents

METHOD FOR SYNTHESIZING 1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-3-FORMAMIDINE HYDROCHLORIDE

The present invention relates to the field of chemical synthesis, and in particular to a method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-formamidine hydrochloride, which is an important intermediate of Riociguat that is an anti-thro

Novel Combination Containing a Stimulator of Soluble Guanylate Cyclase and a Lipid-Lowering Substance

A combination product which comprises as pharmaceutically active ingredients at least one active ingredient component A and at least one active ingredient component B, where active ingredient component A is a direct soluble guanylate cyclase stimulator of

Substituted pyrazole derivatives

The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which the substituents R1, R2, R3, A, X and Y are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.

Novel sulfonamide-substituted pyrazolopyridine derivatives

The invention relates to novel pyrazolopyridine derivatives of formula (I) wherein R1 represents H, Cl or NH2, and R2 and R3 form; together with the heteroatoms to which they are bonded, a five to six-membered heterocycle which can be saturated or partially unsaturated, can optionally contain at least one other heteroatom from the group N, O, S and can be optionally substituted. The invention also relates to salts, isomers and hydrates of said derivatives, in the form of stimulators of soluble guanylate cyclase and as agents for treating cardiovascular diseases, hypertonia, thrombo-embolic diseases and ischaemia, sexual dysfunction, inflammations, and diseases of the central nervous system.

Novel carbamate-substituted pyrazolopyridine derivatives

The invention relates to novel pyrazolopyridine derivatives of the formula (I), wherein R1 represents hydrogen or a di-C1-6-alkylaminocarbonyl group, R2 represents a rest of the formula —O—CO—NR3R4, wherein R3 and R4 are the same or different and represen

Substituted pyrazole derivatives condensed with six-membered heterocyclic rings

The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which R1, R2, R3and A are each as defined, and to processes for their preparation and to their use as medicaments, in pa

Pyridine-substituted pyrazolopyridine derivatives

The present invention relates to new pyrazolopyridine derivatives of the formula (I) in which R1 represents 4-pyridinyl or 3-pyridinyl; R2 represents H, NH2 or halogen; and salts, isomers and hydrates thereof as stimulator

Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase.

The pyrazolopyridine stimulators of soluble guanylate cyclase BAY 41-2272 and 41-8543 were oxidised in rats and dogs at their 5-pyrimidinyl-cyclopropyl and -morpholino residue. These metabolites activate the soluble guanylate cyclase, induce vasoelaxation and thereby may contribute to the in vivo activity of BAY 41-2272 and BAY 41-8543.

NO-independent stimulators of soluble guanylate cyclase

SARs around a novel type of guanylate cyclase stimulator which act by a mechanism different from classical NO-donors are described. Several pyrazolopyridinylpyrimidines are shown to relax aortic rings and revealed a long-lasting blood pressure lowering effect in rats after oral application.